Raina Biosciences has unveiled data from its generative AI platform, GEMORNA, in a study published in Science. GEMORNA leverages transformer-based deep generative models tailored to messenger RNA sequences and untranslated regions to design novel mRNAs with enhanced translational capacity and stability. The platform demonstrated up to a 41-fold increase in expression compared to optimized benchmarks and produced therapeutic mRNAs with significantly improved efficacy in preclinical models. GEMORNA’s versatility extends to circular RNA applications and CAR-T cell enhancement. This AI-driven approach aims to accelerate mRNA therapeutic discovery, expand treatment modalities, and optimize drug properties beyond conventional methods.